Bowel Dysfunction after Low Anterior Resection for Colorectal Cancer: A Frequent Late Effect of Surgery Infrequently Treated.

Autor:	McKenna NP; From the Department of Surgery (McKenna, Habermann), Mayo Clinic, Rochester, MN.; The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (McKenna, Bews, Habermann), Mayo Clinic, Rochester, MN., Bews KA; The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (McKenna, Bews, Habermann), Mayo Clinic, Rochester, MN., Yost KJ; Department of Quantitative Health Sciences (Yost), Mayo Clinic, Rochester, MN., Cima RR; Division of Colon and Rectal Surgery (Cima), Mayo Clinic, Rochester, MN., Habermann EB; From the Department of Surgery (McKenna, Habermann), Mayo Clinic, Rochester, MN.; The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (McKenna, Bews, Habermann), Mayo Clinic, Rochester, MN.
Jazyk:	angličtina
Zdroj:	Journal of the American College of Surgeons [J Am Coll Surg] 2022 Apr 01; Vol. 234 (4), pp. 529-537.
DOI:	10.1097/XCS.0000000000000085
Abstrakt:	Background: The development of major low anterior resection syndrome (LARS) after low anterior resection is severely detrimental to quality of life, yet awareness of it by clinicians and patients and the frequency of treatment of LARS is unclear. Study Design: Patients who underwent low anterior resection for sigmoid or rectal cancer at a tertiary center between 2007 and 2017 (n = 798) were surveyed in 2019 to assess LARS symptoms and report medications or treatment received for LARS. LARS scores were calculated (score range 0-42) and normalized to published data on LARS prevalence in the general population in Europe, stratified by age (<50 or ≥50) and sex. Results: Of the 594 patients (74%) who returned the survey, 255 (43%) were identified as having major LARS (LARS score ≥30). This prevalence was significantly higher than published normative data from Denmark and Amsterdam when stratified by age greater than or less than 50 and sex. Patients with major LARS infrequently reported current use of first-line therapies (antidiarrheal medications 32%, fiber supplements 16%, and both 13%). Only 3% reported receiving second-line therapy of transanal irrigations and/or pelvic floor rehabilitation, and only 1% had undergone third-line therapy of sacral nerve stimulator implantation. Conclusion: Major LARS is common yet seemingly underrecognized by clinicians because less than half of patients are on first-line therapy and practically none are on second- and third-line therapies. Long-term follow-up of patients after low anterior resection, improved preoperative and postoperative education, and continued symptom assessment is necessary to improve treatment of major LARS. (Copyright © 2022 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu